All news

EORTC study published in NEJM shows prolonged survival in stage III melanoma

08/10/2016 A randomized, phase 3 EORTC trial involving patients with resected, high-risk stage III melanoma – published this week in NEJM and presented at the first Presidential Symposium at ESMO – demonstrated that adjuvant treatment with the checkpoint inhibitor ipilimumab significantly improve...

Find us

Avenue Emmanuel Mounier, 83/11
Brussels 1200
Belgium

Contact us

Follow us

Funding